Literature DB >> 22153401

Ocular and systemic findings in a survey of aniridia subjects.

Peter A Netland1, Michele L Scott, John W Boyle, James D Lauderdale.   

Abstract

PURPOSE: To determine the prevalence of ocular and systemic abnormalities in a group of subjects with aniridia.
METHODS: Survey forms developed by Aniridia Foundation International were sent to all members prior to the 2010 AFI member conference. An additional form was provided for completion by physicians caring for patients. Forms were then collected from all members who attended the meeting.
RESULTS: A total of 155 surveys were distributed, of which 83 (53%) were completed. The mean age was 25.4 ± 18.4 years, with 65% sporadic and 35% familial cases, and 2.4% with WAGR (Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation) syndrome. Ocular abnormalities included nystagmus (83%), cataract (71%), dry eye (53%), glaucoma (46%), keratopathy (45%), foveal hypoplasia (41%), strabismus (31%), and retinal disease (5%). The mean age at diagnosis of aniridia was 22.1 months (median, 1.5 months) and glaucoma was 13.6 years (median, 8.5 years). Of 38 subjects with aniridia and glaucoma, 76% were treated medically, and 58% had been treated surgically. In subjects with glaucoma, the mean number (± SD) of glaucoma medications was 1.8 ± 1.3, and number of surgical procedures was 1.7 ± 2.0. Developmental delay was reported in 17%. The mean body mass index and the prevalence of obesity in subjects with aniridia was significantly greater (P = 0.003) than in siblings without aniridia.
CONCLUSIONS: In this study, aniridia was associated with nystagmus and other motility problems, cataract, glaucoma, and keratopathy. Systemic abnormalities included increased average body mass index and obesity, which appeared to occur not only in WAGR syndrome but more broadly in aniridia.
Copyright © 2011 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22153401     DOI: 10.1016/j.jaapos.2011.07.009

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  24 in total

1.  Xenopus pax6 mutants affect eye development and other organ systems, and have phenotypic similarities to human aniridia patients.

Authors:  Takuya Nakayama; Marilyn Fisher; Keisuke Nakajima; Akinleye O Odeleye; Keith B Zimmerman; Margaret B Fish; Yoshio Yaoita; Jena L Chojnowski; James D Lauderdale; Peter A Netland; Robert M Grainger
Journal:  Dev Biol       Date:  2015-02-25       Impact factor: 3.582

2.  [Aniridia syndrome: clinical findings, problematic courses and suggestions for optimization of care ("aniridia guide")].

Authors:  B Käsmann-Kellner; B Seitz
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

3.  Long-term retinal protection by MEK inhibition in Pax6 haploinsufficiency mice.

Authors:  James D Cole; Kara M McHaney; Behnam Rabiee; Jingyi Gao; Carlos Rodriguez; David A Miller; Mingna Liu; Marta Grannonico; Pedro Norat; Hao F Zhang; Ali R Djalilian; Xiaorong Liu
Journal:  Exp Eye Res       Date:  2022-03-01       Impact factor: 3.770

Review 4.  The genetics of glaucoma: Disease associations, personalised risk assessment and therapeutic opportunities-A review.

Authors:  Inas F Aboobakar; Janey L Wiggs
Journal:  Clin Exp Ophthalmol       Date:  2022-01-17       Impact factor: 4.383

5.  Congenital aniridia: etiology, manifestations and management.

Authors:  Monica Samant; Bharesh K Chauhan; Kira L Lathrop; Ken K Nischal
Journal:  Expert Rev Ophthalmol       Date:  2016-03-09

6.  Keratopathy, cataract, and dry eye in a survey of aniridia subjects.

Authors:  David Shiple; Brenton Finklea; James D Lauderdale; Peter A Netland
Journal:  Clin Ophthalmol       Date:  2015-02-10

7.  A Restricted Repertoire of De Novo Mutations in ITPR1 Cause Gillespie Syndrome with Evidence for Dominant-Negative Effect.

Authors:  Meriel McEntagart; Kathleen A Williamson; Jacqueline K Rainger; Ann Wheeler; Anne Seawright; Elfride De Baere; Hannah Verdin; L Therese Bergendahl; Alan Quigley; Joe Rainger; Abhijit Dixit; Ajoy Sarkar; Eduardo López Laso; Rocio Sanchez-Carpintero; Jesus Barrio; Pierre Bitoun; Trine Prescott; Ruth Riise; Shane McKee; Jackie Cook; Lisa McKie; Berten Ceulemans; Françoise Meire; I Karen Temple; Fabienne Prieur; Jonathan Williams; Penny Clouston; Andrea H Németh; Siddharth Banka; Hemant Bengani; Mark Handley; Elisabeth Freyer; Allyson Ross; Veronica van Heyningen; Joseph A Marsh; Frances Elmslie; David R FitzPatrick
Journal:  Am J Hum Genet       Date:  2016-04-21       Impact factor: 11.025

Review 8.  Congenital Aniridia: Clinic, Genetics, Therapeutics, and Prognosis.

Authors:  Pedro Calvão-Pires; R Santos-Silva; F Falcão-Reis; A Rocha-Sousa
Journal:  Int Sch Res Notices       Date:  2014-10-29

9.  Absence of NR2E1 mutations in patients with aniridia.

Authors:  Ximena Corso-Díaz; Adrienne E Borrie; Russell Bonaguro; Johanna M Schuetz; Thomas Rosenberg; Hanne Jensen; Brian P Brooks; Ian M Macdonald; Francesca Pasutto; Michael A Walter; Karen Grønskov; Angela Brooks-Wilson; Elizabeth M Simpson
Journal:  Mol Vis       Date:  2012-11-22       Impact factor: 2.367

10.  Congenital aniridia with cataract: case series.

Authors:  Jin Da Wang; Jing Shang Zhang; Ying Xiong; Jing Li; Xiao Xia Li; Xue Liu; Jing Zhao; Frank F Tsai; Jhanji Vishal; Qi Sheng You; Yao Huang; Xiu Hua Wan
Journal:  BMC Ophthalmol       Date:  2017-07-04       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.